BPC-157 Regulatory Status in Canada
No, oral BPC-157 is not approved for medical use in Canada. BPC-157 has not received authorization from Health Canada for any clinical indication and remains an investigational compound without regulatory approval. 1
Regulatory Framework in Canada
Health Canada has not approved BPC-157 as a prescription medication, natural health product, or over-the-counter therapeutic agent for any medical condition. 1
The drug approval process in Canada requires manufacturers to submit applications to Health Canada for a Drug Identification Number (DIN) and marketing license, followed by review by the Canadian Agency for Drugs and Technologies in Health (CADTH) before provincial formulary listing. 2
BPC-157 has not undergone this regulatory pathway and therefore cannot be legally prescribed, dispensed, or marketed as a therapeutic agent in Canada. 1
Current Regulatory Status Globally
The U.S. FDA has not approved BPC-157 for any medical use, citing the absence of sufficient and comprehensive clinical studies confirming health benefits in humans. 1
BPC-157 was temporarily banned by the World Anti-Doping Agency (WADA) in 2022, though it is not currently listed as banned. 1
The compound remains available through non-regulated sources including online retailers and compounding pharmacies operating outside standard regulatory oversight. 3, 4
Clinical Evidence Limitations
Only three pilot studies in humans exist: one examining intraarticular knee injection, one for interstitial cystitis, and one assessing intravenous safety/pharmacokinetics. 3
Despite robust preclinical animal data showing potential benefits for musculoskeletal healing, no large-scale, well-designed human clinical trials have been conducted to establish safety or efficacy. 3, 4
The limited human data (12 patients total across published studies) is insufficient to meet regulatory standards for drug approval in Canada or other jurisdictions. 5, 6
Important Safety Considerations
Unregulated manufacturing poses contamination risks and quality control concerns, as products are obtained through non-pharmaceutical channels. 4
While preclinical studies showed no adverse effects across organ systems and small human pilots reported no side effects, comprehensive clinical safety data do not exist. 6, 3
Patients seeking BPC-157 through online sources or compounding pharmacies are using an investigational compound without regulatory oversight, medical supervision, or quality assurance. 1, 3
Access Pathways That Do NOT Apply to BPC-157
Canada's Special Access Program (which provides access to non-approved drugs for serious conditions) has been used for other investigational agents like sodium stibogluconate for leishmaniasis, but BPC-157 is not available through this mechanism. 7
Unlike natural health products such as cytisine (which received approval for smoking cessation), BPC-157 has not been authorized even under the less stringent natural health product regulatory framework. 8